Enhancement of exposure therapy for social anxiety disorder with testosterone: A randomized placebo controlled clinical trial - Testosterone enhancement of exposure therapy in SAD

ProPersona (Nijmegen)0 个研究点目标入组 54 人开始时间: 待定最近更新: 2024年6月11日

适应症

试验速览

暂无简介。

•- Woman, 18-45 years old
•- Social Anxiety Disorder (SAD) as established with a structured interview (MINI), and with speech anxiety as primary fear
•- Self reported SAD symptoms above clinical cut-off (score > 30 on the Liebowitz Social Anxiety Scale)

•- Prior non response to exposure therapy (i.c. speech exposure) for SAD symptoms, as defined by the patient*s report of receiving specific and regular exposure assignments as part of previous therapy.
•- Entry of patients with other mood or anxiety disorders will be permitted in order to
•increase accrual of a clinically relevant sample; however in cases where SAD is not judged
•to be the predominant disorder, participants will not be eligible.
•- Psychosis or delusion disorders (current or in the past)
•- Patients with significant suicidal ideations or who have enacted suicidal behaviors within 6
•months prior to intake will be excluded from participation and referred for appropriate clinical
•intervention.
•- Mental retardation
•- Substance abuse or alcohol dependence
•- Somatic illness
•- Women of childbearing potential that are not willing to use an active form of birth-control during the trial
•- Pregnancy or lactation
•- Infertility
•- Antipsychotic medication
•- Participants that use antidepressants or benzodiazepines will not be excluded, but have to be on a stable dose for at least 6 weeks prior to enrollment.
•- Insufficient ability to speak and write Dutch

发起方

ProPersona (Nijmegen)